Safe and pragmatic use of sodium–glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement Kalra S, Ghosh S, Aamir A H, Ahmed M, Amin
Glucose Metabolism in the Kidney: Neurohormonal Activation and Heart Failure Development | Journal of the American Heart Association
Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors - Yakovleva -
SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence
IJPSR (2009), Issue 1, Vol
A new era in the management of type 2 Diabetes Various studies have thrust the sodium glucose cotransporter 2 (SGLT2) inhibitors ('gliflozin') into the forefront of T2DM guidelines. Glycaemic control can decrease microvascular complications in patients with ...
SGLT2 Inhibitors: A New Class of Diabetes Medications
Results for SLGT2 | GrepMed
SGLT2 Inhibitors: A Review of Canagliflozin
Dapagliflozin- a novel SGLT2 inhibitor
Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors | SpringerLink
SGLT2 inhibitor - Wikipedia
SGLT2 inhibitors, an accomplished development in field of medicinal chemistry: an extensive review | Future Medicinal Chemistry
SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome | American Society of Nephrology
Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease | Diabetes
The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit | SpringerLink
Canagliflozin (Mechanism of action) | Download Scientific Diagram
Top 3 Anti-Aging Medications
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure | Heart
Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks - Journal of Biological Chemistry
EMPA-REG OUTCOME: The Nephrologist's Point of View - ScienceDirect
A Potential Mechanism of Cardio-Renal Protection with Sodium-Glucose Cotransporter 2 Inhibitors: Amelioration of Renal Congestio
A Variation on the Theme: SGLT2 Inhibition and Glucagon Secretion in Human Islets | Diabetes
Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application | SpringerLink
Top 10 Things Invokana Patients Need To Know... - Childers, Schlueter & Smith, LLC
